<DOC>
	<DOCNO>NCT00678275</DOCNO>
	<brief_summary>This multicenter , prospective phase III-study compare administration ATG FRESENIUS NON-administration ATG FRESENIUS myeloablative conditioning regimen follow allogeneic hematopoeitic stem cell transplantation HLA-identical sibling patient acute Leukemia . This clinical trial show administration ATG FRESENIUS reduce risk chronic Graft-versus-Host disease allogeneic stem cell transplantation HLA-identical sibling .</brief_summary>
	<brief_title>Chronic Graft-versus-host Disease ( cGvHD ) Prophylaxis With Without ATG Prior Stem Cell Transplantation ( SCT ) From HLA-identical Siblings Patients With Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Acute myeloid leukemia first subsequent complete remission ( denovo secondary AML ) Acute lymphoblastic leukemia first subsequent complete remission Patient 's age : 18 65 year Myeloablative standard condition HLAidentical sibling ( HLAA , HLAB , HLADRB1 HLADQB1 ) No major organ dysfunction Patient 's write consent No complete remission time randomization Severe irreversible renal , hepatic , pulmonary cardiac disease , Total bilirubin , SGPT SGOT 5 time upper normal level leave ventricular ejection fraction &lt; 30 % Creatinine clearance &lt; 30 ml/min DLCO &lt; 35 % and/or receive supplementary continuous oxygen Positive serology HIV Pregnant lactate woman Serious psychiatric psychological disorder Progressive invasive fungal infection time registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
</DOC>